academic article

• Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial..  Lancet neurology.  19:988-997. 2020
• Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis..  The New England journal of medicine.  376:221-234. 2017
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis..  The New England journal of medicine.  376:209-220. 2017
• Randomized study combining interferon and glatiramer acetate in multiple sclerosis..  Annals of neurology.  73:327-340. 2013
• Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010..  International journal of MS care.  14:105-114. 2012
• GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study..  Neurology.  72:806-812. 2009